Introduction
============

Paratuberculosis poses a big challenge to Veterinary Medicine and in particular to ruminant production. Since the first description of the disease in 1895 in a cow from Oldenburg, Friesland, its etiological agent, *Mycobacterium avium*subsp. *paratuberculosis*(MAP), has been shown to cause the disease in the majority of wild and domestic ruminant species \[[@B1],[@B2]\]. This microbe is also present in many other hosts as well as the environment \[[@B3],[@B4]\]. Even though the most important mycobacterial infection in animals, bovine tuberculosis, has been successfully controlled in nearly all developed countries, the other important mycobacterial infection, paratuberculosis, remains an unsolved problem for the veterinary scientific community still incapable of reaching a consensus on the better way to deal with it. This is so despite large control efforts in different countries during the past three decades.

The mounting evidence showing that MAP is a factor in the pathogenesis of human inflammatory bowel disease (IBD) has increased the pressure to overcome this challenge. In spite of this, most of the undertakings are nevertheless based on the old principle that the only way to control an infectious disease is to eradicate its agent. This principle has worked well for some acute infections in times of survival struggle and profligate use of means but is increasingly difficult to apply because of demonstrated lack of efficacy and sustainability philosophy \[[@B5],[@B6]\]. We are no longer faced with a live or death dilemma due to infectious diseases, but we have to deal with a need to increase productivity for the sake of improved and prolonged use of scarce resources. From this perspective, it is necessary to simultaneously exploit the three classical main approaches to eradicate or reduce the impact of paratuberculosis in herds or flocks. These are: 1) to introduce management changes to decrease the transmission of MAP, 2) to apply test and cull practices to eliminate the sources of infection, 3) to vaccinate replacers in order to increase their resistance to infection. The advantages and drawbacks of these strategies will be briefly examined.

Management measures to decrease transmission of MAP
---------------------------------------------------

Management changes to reduce the transmission rate are widely accepted strategies that are compatible with all other approaches \[[@B7]\]. Furthermore, these changes have other positive side effects on farm productivity. Management measures focus mainly on avoiding contact between infected and susceptible young animals \[[@B8]\]. These measures include separating offspring from dams immediately after birth, feeding calves paratuberculosis-free colostrum supplement and milk replacement, raising replacement heifers in separate locations, avoiding manure fertilization of fields where replacement heifers grace, improving general farm hygiene, and eliminating practices that can bring infected foods or materials in contact with susceptible animals. In practice, it implies duplication of facilities and equipment, and meticulous working procedures. Also, another very important factor in the spread of paratuberculosis, which complicates the control of this disease through management measures, is the ability of MAP to survive in the environment for around one year \[[@B9],[@B10]\]. Given the different settings and economic constraints of each individual farm, control measures may greatly vary form farm to farm. In addition, control measures should not be neglected when new animals are brought into a herd. Microbiological and serological results of all new animals, as well as, the paratuberculosis status and history of the herd of origin should always be taken into account before introducing new animals into the farm.

Although these measures might be viable for large dairy farms, the required changes may not be economical for many small dairy farms and are probably impossible to implement in beef cattle and sheep operations due to costs and disrupting effects. Moreover, these measures usually yield no immediate results and are easily abandoned when other productive constraints become more pressing \[[@B11]\]. In summary, this type of strategy has low engaging force and has little chance of being widely and successfully implemented in a whole region.

Culling strategies to eliminate sources of infection
----------------------------------------------------

Three variants of the testing and culling strategy prevail depending on the diagnostic method used to detect infected animals: fecal culture, ELISA or Polymerase Chain Reaction (PCR). The slow turn around rate or the low sensitivity of some of these test are the major problems in the efforts to control the disease \[[@B12]\].

Fecal culture and culling
-------------------------

It is generally accepted that this method detects infected animals first and is the most sensitive method \[[@B13],[@B14]\]. Since it is based on identifying the agent when it is shed into the environment, culling these animals has a direct effect in preventing new infections. Fecal positive animals will also become clinical cases, and, therefore, the most visible effect of culling them is that clinical cases quickly disappear. The main problem with this approach is that the laboratory test is expensive, requires specialization, and its results are not available for several weeks or even months. As a result, progress in control of the disease is slow and often rather disappointing since positive animals keep on appearing over the years even after periods of negative results and absence of clinical cases. Its use for sheep and goats is prohibitively expensive unless it is carried out in pools. Another problem with this approach in farms heavily contaminated with MAP or in farms with super-shedders (animals that excrete 10,000 to 10 million MAP bacteria per gram of manure)\[[@B15]\] is the elimination of uninfected animals that give positive MAP results just because they are passing MAP bacteria through their gastrointestinal tract. This problem also affects PCR and culling strategy.

ELISA and culling
-----------------

The ELISA test for paratuberculosis is generally considered to be highly specific, but of low sensitivity \[[@B14]\]. ELISA\'s simplicity, speed, low cost, and potential for automation makes it an ideal tool for laboratory diagnostic work \[[@B16]\]. The problems with ELISA test are that it has not yet been well studied how it will perform to control the disease and that the minimal sensitivity to reach eradication in a reasonable period of time is not guaranteed. In the best case scenario, inferring from the experience with fecal culture it can be assumed that ELISA testing and culling, if done often enough, will prevent the appearance of clinical cases, and slightly decrease the transmission risk. Additional problems with paratuberculosis ELISA are that sample handling appears to affect substantially the results of the test \[[@B17]\] and that the different commercially available diagnostic kits have very different efficacies \[[@B18],[@B19]\], which therefore, can severely affect control programs. Given its costs are low and the results are obtained in less than a week, it is more easily accepted when positive results keep trailing along time since it is always possible to intensify control by testing more frequently. The regional ELISA specific strategies implemented up to now are rather complex and still not proven successful.

PCR and culling
---------------

The new type of strategy, albeit sparsely implemented, is the combination of PCR analysis of feces and culling of positive animals. In theory, this strategy should detect animals early in the infection process before antibodies are developed, and thus can quickly reduce the overall bacterial burden in the farm. However, the costs and the requirement of specialized personnel are major drawbacks of this technique. Until recently costs of PCR were extremely high for its use in animal health diagnostics. Dramatic reductions in reagent prices accompanied by improvements in technique sensitivity and especially in efficient high-throughput processing of samples and extraction of nucleic acids have made this approach a valuable strategy due to its high specificity, good sensitivity, and fast turnaround time \[[@B20],[@B21]\]. The majority of paratuberculosis PCR detection tests are based on the detection of IS900 sequence, which has the benefit of multiple copies of target DNA per bacteria (higher sensitivity) but the disadvantage of a lower specificity since a few environmental mycobacteria also contain this insertion sequence. Other tests use MAP specific single copy genes (i.e. F57, 251) with theoretically lower sensitivity but higher specificity \[[@B22],[@B23]\]. Multiplex PCRs, using combinations of target genes, have also been reported \[[@B24]\]. PCR has the additional benefit over the ELISA technique that, like fecal culture, it can provide quantitative bacterial content results, and thus high shedders and medium shedders can readily be identified and eliminated. Recently in the Netherlands, fecal culture has been replaced by a PCR based test in the Dutch paratuberculosis control program. As with the ELISA and culling strategy, PCR and culling is not yet proven in the field, however, a new study by Lu et al has shown that the use of faster detection tests such as PCR might be important in farms with poor management \[[@B25]\].

Vaccination
-----------

Vaccination, as a control measure for paratuberculosis, is probably the less accepted strategy although it is or has been used in all countries with substantial problems with this disease \[[@B26],[@B27]\]. It is a highly cost-efficient strategy, which clearly prevents the appearance of clinical cases if done properly \[[@B27]\]. Vaccination strategies have been widely implemented for sheep in different countries with great success \[[@B27]\]. The main drawback to vaccination is that, since vaccines used in the field are not DIVA (differentiating infected from vaccinated), it can interfere with serological diagnosis of paratuberculosis and tuberculosis infections. Thus MAP vaccination might not allow eradication of the disease and it can interfere with national tuberculosis eradication programs. The latter is in fact the major hurdle affecting MAP vaccine approval for cattle by medical and agricultural authorities all over the world and the major deterrent for pharmaceutical companies to design new MAP vaccines for cattle. The most widely used tuberculosis diagnostic test in cattle is the single intradermal tuberculin test, and some cattle vaccinated with the currently available ovine or experimental MAP vaccines will become positive to this test. According to legislation in many countries, these animals are banned from international trade and should be slaughtered unless it can be proved that they are not infected with tuberculosis. New tuberculosis immunological diagnostic test, such as the gamma interferon release assay or the Enferplex™ TB assay, could help in the differentiation between MAP vaccinated and tuberculosis infected animals, but, improvements of these test might be required, since interference with tuberculosis diagnosis can still occasionally occur in MAP infected animals \[[@B28]\]. However, a modification of the single intradermal tuberculin test, the comparative intradermal tuberculin test, could solve the interference problem in the vast majority of cases. This test, which has been available for many years and is actually an official tuberculin test according to the OIE and EU legislation, consists of the simultaneous intradermal injection in two different sites of tuberculins from *Mycobacterium bovis*(PPDbov) and *Mycobacterium avium*subsp. *avium*(PPDav). Higher reactivity to the avian tuberculin indicates infection or vaccination with avian type mycobacteria and allows to rule out mammal tuberculosis infection according to standardized criteria.

An additional drawback to MAP vaccination, which at least in sheep appears not to be of economical relevance \[[@B29]\], is the granulomatous lesion at the injection site produced by most oil-based bacterin vaccines.

In summary, there are several strategies for paratuberculosis control, but there is no generalized consensus on which one or which combination of strategies should be the standard approach. In our opinion, this is in part due to the fact that paratuberculosis control programs emphasize too heavily MAP eradication.

Pathogenic background
---------------------

### MAP distribution

If we take a general view of our knowledge on paratuberculosis, we should point out that MAP is not a classical infectious agent fully complying with Koch\'s postulates. Indeed, we know that many experimental infections fail to establish the infectious agent in the intestinal tissue and to cause the disease \[[@B30]-[@B33]\]. We also know that frequently the initial focal lesions do not progress to clinical stages. More recent evidence has revealed that it is not rare for herds with no clinical history of paratuberculosis and even with a history of negative fecal culture to occasionally show positive fecal culture results \[[@B34]\]. In addition, recent studies on paratuberculosis prevalence have revealed that as many as 60% of some national herds are actually infected \[[@B35]\]. Finally, Pickup and collaborators have shown that MAP is present in the environment at a previously unsuspected high frequency \[[@B4]\]. All this evidence indicates that MAP might be a necessary, but not a sufficient cause of paratuberculosis. Under these conditions, we should therefore ask ourselves: Is paratuberculosis eradication a realistic goal? Is it necessary? Is it profitable for the society in general? Answers to these questions are not readily available because we lack accurate information on the actual distribution of MAP and its potential impact on human health. Reviewing aspects of the pathogenesis and epidemiology may lay the grounds on which control alternative(s) to choose.

### Forms of infection

Multiple forms of infection can be observed in MAP infected animals. The form present in an animal will not only depend on the progression of the infection or stage of the disease, but also on many other factors including an individual\'s genetic resistance or susceptibility to the pathogen, age at the time of infection, and previous exposure to other environmental mycobacteria. On Figure [1](#F1){ref-type="fig"}, we illustrate the balance between the infection and the animal\'s immune system and their corresponding forms of infection. According to different studies, about 46% of cattle, 51% of sheep, and 50% of goats in a MAP-contaminated environment do not show any signs of infection \[[@B36]-[@B38]\]. Since these animals live in a heavily contaminated environment, they must continuously be exposed to MAP, and, therefore, they either prevent the infection or very quickly clear up the establishment of local infection foci. Because it is not rare for such animals to carry MAP and plenty of experimental evidence has shown that administration of large amounts of MAP not always results in the development of a full blown infection, quite the opposite frequently produces very regressive lesions, the more likely explanation is that there is a balance between MAP and the host that in about half of the exposed individuals results in containing the infection (Figure [1](#F1){ref-type="fig"}). Beyond this balance point there are also different stages of infection. About 19% of cattle, 24% of sheep and 12% of goats carry an infection which is very focal and delimited. Around 17% and 9% of cattle and sheep, respectively, have multifocal forms. Of the animals presenting diffuse forms, approximately 19% of cattle, 16% of sheep and 38% of goats develop into diffuse forms which lead to animals showing clinical signs and to their death.

![**Immunopathological model of paratuberculosis**. Continuous exposure of animals to MAP results in a dynamic balance where infection never gets established or is controlled by an efficient innate immune response in about half of the farm population, while in the other half it progresses to subclinical delimited focal or multifocal forms and, in a smaller fraction, to diffuse lymphocytic (cellular or Th1 type) or non-lymphocytic (humoral or Th2 type) forms that will result in open clinical disease.](1476-8518-9-8-1){#F1}

### Vaccine types

Both live (non-attenuated and attenuated) and killed whole cell vaccines have been used against paratuberculosis. In a few cases, subunit vaccines consisting of sonicated bacteria, bacterial cell fractions or recombinant MAP antigens have been used but they have shown a much lower degree of protection \[[@B39],[@B40]\]. More recently, DNA vaccines, consisting of the inoculation of mammalian expression vectors containing MAP genes have also been used in mice, humans and sheep but not in cattle \[[@B41]-[@B47]\]. Most MAP vaccine formulations have been based on mycobacteria and a water-in-oil emulsion (olive, mineral, liquid, paraffin, etc). Some have also an irritant like pumice powder in order to increase and stimulate the local inflammatory response, and therefore enhance the immunogenicity of the vaccine. The goal of these vaccines is to establish a focus of inflammation where the antigens can permanently stimulate the host immune system. Under this principle, it would not be necessary to revaccinate animals because the slow liberation of antigens from the vaccination site keeps on stimulating the immune system, at least during the period before the age of initial clinical disease presentation.

### Vaccination age

Paratuberculosis vaccines are recommended for exclusive use in very young animals on the grounds that this is necessary to prevent infection and to decrease interfering responses with the diagnosis of tuberculosis. Actually, the experience on animals older than 1 month is rather scarce, however recent studies on the pathogenesis as well as some field data suggest that vaccination of adult or subadult animals might have some management (no need for separate handling, vaccination of only replacers) and therapeutic (stronger humoral and cellular responses) advantages that need to be taken into account \[[@B48],[@B49]\]. More recent evidence form Australian sheep vaccination trials indicate that there might be an age threshold for vaccine efficacy that can be drawn at around 8 months of age \[[@B50]\].

Reassessment of vaccination results
-----------------------------------

### Literature on vaccination

There is an increasing number of vaccination studies in ruminant species focused on different aspects of the use of MAP vaccines including two recent reviews on the topic \[[@B51],[@B52]\]. The most recent review by Rosseels et al. focused mainly on the immunological aspects of MAP vaccination \[[@B52]\]. For the purpose of the present review we have used only vaccinations studies of cattle, sheep or goats reporting production, epidemiological or pathogenetic effects and data that could be used to estimate the reduction rates of damage or contamination. Production effects relate to the losses measured as the frequency of clinical cases or mortality rates. We considered epidemiological effects as the microbiological contamination risks measured by the frequency or amount of MAP isolations in fecal or tissue cultures. And finally, pathogenetic effects pertain to the modification in the course of the disease as measured by the frequency of specific histopathological lesions. Searches of published material before January 2010 were run using three strategies: First, specific searches of combinations of the words vaccination, vaccine and paratuberculosis were run on Current Contents or Pubmed and the hits were screened for articles meeting the conditions stated above. Second, the same combinations of words were used in Google (<http://www.google.com>) to obtain studies from doctoral dissertations and other sources. Third, literature data on vaccination trials collected over a period of 25 years at NEIKER was also examined systematically. More than half the published studies included in this meta-analysis describe field reports, which actually might give a better view of the whole problem of vaccination, since highly controlled experimental trials might be misleading because of the lack of interferences from field conditions.

The very first report on paratuberculosis vaccination of cattle is that by Vallée and Rinjard in 1926 \[[@B53]\]. It is not until 1960 that a similar vaccine was reported to have been used in sheep \[[@B54]\]. As for goats, although it is known that vaccines have been used in Spain in the 70\'s, the first written report on its efficacy dates back to 1985 in Norway \[[@B26]\].

### Paratuberculosis vaccination meta-analysis

Taking worldwide published reports on paratuberculosis vaccination available to us but not restricted to peer-reviewed papers, we have classified the studies according to species (cattle, sheep or goats), and type of evaluation of vaccine efficacy (production, epidemiological or pathogenetic effects). We have kept only those studies were the authors reported either vaccinated versus control group or pre-vaccination versus post-vaccination cohorts in numerical terms. In all, except in one study where a scoring system was used for MAP isolation, results were presented as the frequency of positive/affected individuals over total animals in the study. We have not been overly critical on the criteria applied by authors, but instead we have assumed that they knew well the disease and that their study design was sound.

All data have been transformed into a reduction percent calculated as the frequencies difference divided by the frequency in the control group. For each category of species and type of evaluation, we have calculated a size-weighted reduction average for the whole set of studies in that category. The same size-weighting method has been previously used to calculate a standard deviation in order to define the 95% confidence limits of the estimate \[[@B55]\].

Results
=======

A total of 118 experiments from 63 reports and 14 countries have been used for the meta-analysis in this review (Tables [1](#T1){ref-type="table"} and [2](#T2){ref-type="table"}). The USA was the country with the highest number of studies included (26.3%), followed by New Zealand (14.4%) and then closely by Spain (13.6%). Some countries, such as the USA, have studies throughout the years, however, interest in MAP vaccination studies change among countries. For example, early large studies in the UK and France, gave way to studies in The Netherlands, New Zealand, Australia and Spain. This pattern might reflect MAP prevalence levels and research funding priorities in the different countries, but most likely it is also biased by administrative regulations limiting the availability of a successful commercial vaccine for sheep and goats (Gudair™), which is being widely used in countries with large sheep populations. 45 experiments were conducted in cattle, 49 in sheep, and 24 in goats (Table [2](#T2){ref-type="table"}). Apart from the studies where small ruminants were used either because they were the target species of the commercial vaccine or because they are an easier to handle and a less costly animal model, there is a relation between the type of animal used in the study and the main livestock in the country.

###### 

Countries where the vaccination experiments\* used in the meta-analysis were carried out.

  Country          Number of Experiments   Percent
  ---------------- ----------------------- ---------
  Australia        12                      10.2
  Denmark          1                       0.8
  France           5                       4.2
  Germany          1                       0.8
  Greece           6                       5.1
  Hungary          1                       0.8
  Iceland          2                       1.7
  India            4                       3.4
  Netherlands      12                      10.2
  New Zealand      17                      14.4
  Norway           1                       0.8
  Spain            16                      13.6
  United Kingdom   9                       7.6
  United States    31                      26.3
  Total            118                     

\* An experiment is defined as vaccine trial whose results are measured according to one of the three outcome variables: clinical signs, MAP isolation, gross or microscopic lesions.

###### 

Experiments and reports used for the meta-analysis.

  Species   Experiments   Reports\*
  --------- ------------- -----------
  Cattle    45            33
  Sheep     49            21
  Goats     24            9

\* A report is a publication or communication that might contain results of one or more experiments.

Half of the studies are field trials where animals were naturally exposed to MAP. In these studies, results were assessed either by comparison between initial prevalence before vaccination, and final prevalence some time post-vaccination, or by following up a matched group within the same herd or flock. The later type of studies, when the control group is housed with vaccinated animals, frequently underestimates the positive effects of vaccination, because as herd immunity increases, bacterial shedding into the environment is reduced and thus the probability of a natural infection in the control group is also reduced. In three experiments the assessment was done using control unvaccinated herds, and one consisted of a questionnaire on clinical incidence in farms before and after using vaccination.

Tables [3](#T3){ref-type="table"}, [4](#T4){ref-type="table"} and [5](#T5){ref-type="table"} summarize the results of all vaccination experiments used for the meta-analysis. Less than a third of them are not standard peer review journal publications (Doctoral Dissertations, non-peer review magazines, conference proceedings, bulletin reports, memoranda, or other types of documents). Some appear to be advances of results that have been published later. Since the information is different, we have treated them as individual experiments, although we were aware that they might introduce a bias to underestimate vaccination positive effects, particularly regarding culture results because of their lack of time span for the vaccine to make its mid- to long-term effects.

###### 

Production effects (Paratuberculosis clinical cases or mortality rates).

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Vaccine            Country and reference   Year               Number of animals     Age at vaccination       Reduction\   Type of trial                          
                                                                                                               (%)                                                 
  ------------------ ----------------------- ------------------ --------------------- ------------------------ ------------ --------------- ------------- -------- ----------------------
                                                                                      **Cattle**                                                                   

                                                                                                                                                                   

  NCV                Live                    6 strains          Oil                   U.S.A. \[[@B65]\]        1935         20              1 m           100,00   E, MC, CC

  Weybridge          Live                    316F               P/O/P                 U.K. \[[@B66]\]          1959         63401           1 m           93.45    F, IF, CC

  Weybridge          Live                    316F               P/O/P                 U.K. \[[@B67]\]          1964         2440            1 m           98.36    F, IF, CC

  Weybridge          Live                    316F               P/O/P                 U.K. \[[@B68]\]          1965         84              1 w           46.67    E, MC, CC

  Weybridge          Live                    316F               P/O/P                 U.K. \[[@B69]\]          1982         150000          1 m           99.06    F, IF, CC

  Fromm              Killed                  *M.a.a*strain 18   Oil                   U.S.A. \[[@B70]\]        1983         48              1 m           35.29    F, MC, CC

  \-                 Live                    316F               P/O/P                 France \[[@B61]\]        1988         902             1 m           87.34    F, IF, CC

  \-                 Live                    316F               P/O/P                 France \[[@B61]\]        1988         1037            1 m           97.22    F, IF, CC

  Lelystad           Killed                  \-                 Oil                   Netherlands \[[@B59]\]   1988         851             1-24 m        87.05    F, IF, CC

  Lelystad           Killed                  \-                 Oil                   Netherlands \[[@B71]\]   1992         61050           1 m           91.82    F, MC, CC

  NCV                Killed                  \-                 Oil                   Netherlands \[[@B72]\]   1994         337             1 m           79.01    F, IF, CC

  NCV                Killed                  \-                 Oil                   Netherlands \[[@B37]\]   1996         573             1 m           68.14    F, CC

                                                                                                                                                                   

  **Average**        **96.02 ± 0.01**                                                                                                                              

                                                                                                                                                                   

  **Sheep**                                                                                                                                                        

                                                                                                                                                                   

  NCV                Live                    316F               Oil Paraffin          Greece \[[@B73]\]        1988         1448            1 m           76.14    F, MC, TM

  NCV                Live                    316F               Oil Paraffin          Greece \[[@B73]\]        1988         5526            Adults        28.74    F, MC, TM

  Lio-Johne          Live                    316F               Oil                   Spain \[[@B74]\]         1993         1201            Adults        78.29    F, MC, CC

  Lio-Johne          Live                    316F               Oil                   Spain \[[@B75]\]         1995         570             1 m           52.55    F, MC, TM

  Weybridge          Live                    316F               P/O/P                 U.K. \[[@B76]\]          1993         830             Adults        89.86    F, IF, CC

  Neoparasec & NCV   Live & Killed           316F\              Oil\                  Spain \[[@B77]\]         1995         857             Adults        54.55    F, IF, CC
                                             -                  Oil                                                                                                

  Neoparasec         Live                    316F               Oil                   New Zealand \[[@B78]\]   2000         28              1-1.5 m       71.43    E, MC, CC

  Gudair             Killed                  316F               Oil                   Australia \[[@B79]\]     2003         8000            3, 8 m, 2 y   87.50    F, IF, mort rate

  Gudair             Killed                  316F               Oil                   Australia \[[@B80]\]     2004         1200            1-4 m         90.00    F,MC, mort reduction

  Gudair             Killed                  316F               Oil                   Australia \[[@B34]\]     2006         400             1-3 m         91.25    F, MC, TM

  Gudair             Killed                  316F               Oil                   New Zealand \[[@B81]\]   2009         65              4 m           78.57    E, MC, CA

  NCV                Killed                  316F               Lipid-K formulation   New Zealand \[[@B81]\]   2009         65              4 m           57.14    E, MC, CA

  NCV                Live                    316F               Lipid-K formulation   New Zealand \[[@B81]\]   2009         65              4 m           14.29    E, MC, CA

  NCV                Live                    316F               Lipid-K formulation   New Zealand \[[@B81]\]   2009         65              4 m           35.71    E, MC, CA

                                                                                                                                                                   

  **Average**        **67.57% ± 0.35**                                                                                                                             

                                                                                                                                                                   

  **Goats**                                                                                                                                                        

                                                                                                                                                                   

  NCV                Live                    316F               Oil Paraffin          Greece \[[@B73]\]        1988         2178            1 m           82.78    F, MC, TM

  NCV                Live                    316F               Oil Paraffin          Greece \[[@B73]\]        1988         7773            Adults        34.52    F, MC, TM

                                                                                                                                                                   

  **Average**        45.08 ± 0.39                                                                                                                                  
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

NCV: non-commercial vaccine; Weybridge: Central Veterinary Laboratory, Weybridge, UK; Fromm: Fromm Laboratories, Grafton, Wisconsin USA; Lelystad: Central Veterinary Institute, Lelystad, The Netherlands; Lio-Johne, Ovejero, Spain; Neoparasec: Neoparasec^®^, Merial; Gudair: Gudair^®^, CZ Veterinaria/Pfizer; P/O/P Paraffin, Olive Oil, Pumice Stone Powder; y: year(s); m: month(s); w: week(s); d: day(s); F: Field trial; E: Experimental infection; MC: Comparison to matched controls; IF: Comparison of initial versus final prevalence; TM: Total mortality; CC: clinical cases; NVH: Comparison to non-vaccinating herds.

###### 

Epidemiological effects (*Mycobacterium avium*subsp. *paratuberculosis*isolation from faeces or tissues).

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Vaccine            Country and reference   Year                       Number of animals     Age at vaccination       Reduction (%)   Type of trial                         
  ------------------ ----------------------- -------------------------- --------------------- ------------------------ --------------- --------------- ------------ -------- ---------------
  **Cattle**                                                                                                                                                                 

                                                                                                                                                                             

  NCV                Live                    6 strains                  Oil                   U.S.A. \[[@B65]\]        1935            20              1 m          -14.29   E,TC

  Weybridge          Live                    316F                       P/O/P                 U.K. \[[@B68]\]          1965            84              1 w          11.54    E, MC, TC

  Weybridge          Live                    316F                       P/O/P                 Australia \[[@B82]\]     1971            82              1 m          24.18    F, IF,MC, TC

  NCV                Live                    avirulent                  P/O/P                 U.S.A. \[[@B83]\]        1974            16              16 d         81.47    E, MC, FC

  NCV                Live                    avirulent                  P/O/P                 U.S.A. \[[@B83]\]        1974            16              16 d         0.00     E, MC, TC

  Fromm              Killed                  *M.a.a*strain 18           Oil                   U.S.A.\[[@B70]\]         1983            158             1 m          79.28    F, MC, FC

  Fromm              Killed                  *M.a.a*strain 18           Oil                   U.S.A. \[[@B70]\]        1983            3060            1 m          99.11    F, IF, FC

  NCV                Live                    316F                       Oil                   Denmark \[[@B84]\]       1983            5446            1 m          92.90    F, MC, FC

  Lelystad           Killed                  \-                         Oil                   Netherlands \[[@B71]\]   1992            2065            1 m          -21.25   F, IF, FC

  NCV                Live                    316F                       P/O/P                 France \[[@B85]\]        1992            22988           1 m          81.68    F, IF/MC, FC

  Phylaxia           Killed                  5889 Bergey                Oil                   Hungary \[[@B86]\]       1994            2738            1 m          94.70    F, IF, FC

  NCV                Killed                  \-                         Oil                   Netherlands \[[@B72]\]   1994            499             1 m          -36.72   F, IF, TC

  NCV                Killed                  \-                         Oil                   Netherlands \[[@B37]\]   1996            573             1 m          13.34    F, IF, TC

  Mycopar            Killed                  *M.a.a*strain 18           Oil                   U.S.A.\[[@B87]\]         2000            372             \< 35 d      71.43    F, MC, FC

  NCV                Killed                  \-                         Oil                   Netherlands \[[@B88]\]   2001            4452            1 m          33.83    F, NVH, FC

  Neoparasec         Live                    316F                       Oil                   Germany \[[@B89]\]       2002            521             1 m          86.87    F, MC, FC

  Mycopar            Killed                  *M.a.a*strain 18           Oil                   U.S.A. \[[@B58]\]        2003            10              7 d          -28.00   E, MC, FC, TC

  Mycopar\           Killed                  *M.a.a*strain 18           Oil                   U.S.A. \[[@B58]\]        2003            10              7 d          32.00    E, MC, FC, TC
  IL-12                                                                                                                                                                      

  Mycopar            Killed                  *M.a.a*strain 18           Oil                   U.S.A. \[[@B58]\]        2003            14              8 d          40.00    E, MC, FC, TC

  Mycopar\           Killed                  *M.a.a*strain 18           Oil                   U.S.A. \[[@B58]\]        2003            14              8 d          23.60    E, MC, FC, TC
  IL-12                                                                                                                                                                      

  Silirum            Killed                  316F                       Oil                   Spain \[[@B90]\]         2005            14              2 m          62.50    E, MC, TC

  NCV                Rec                     Hsp70                      DDA                   Netherlands \[[@B39]\]   2006            20              1 m\         37.50    E, MC, FC
                                                                                                                                                       boost 11 m            

  Mycopar            Killed                  *M.a.a*strain 18           Oil                   U.S.A. \[[@B91]\]        2006            213             \< 35 d      77.12    F, MC, FC

  NCV                Rec                     MAP (85A, 85B, 85C, SOD)   MPLA +/- IL12 RIBI    U.S.A. \[[@B92]\]        2008            24              5-10 d       41.67    E, MC, FC, TC

  Silirum            Killed                  316F                       Oil                   U.S.A. \[[@B93]\]        2009            12              14 d         84.61    E,MC,TC

  Silirum            Killed                  316F                       Oil                   Spain \[[@B49]\]         2009            371             all ages     68.20    F, IF, FC, FP

                                                                                                                                                                             

  **Average**        **72.55 ± 0.29**                                                                                                                                        

                                                                                                                                                                             

  **Sheep**                                                                                                                                                                  

                                                                                                                                                                             

  NCV                Killed                  101 sheep & VB/4 cattle    Oil                   U.K. \[[@B94]\]          1961            44              1 m          52.63    E, MC, TC

  NCV                Killed                  \-                         Oil                   U.K. \[[@B95]\]          1962            126             1 m          29.05    E, MC, TC

  Lio-Johne          Live                    316F                       Oil                   Spain \[[@B74]\]         1993            1201            Adults       80.01    F, MC, TC

  Neoparasec         Live                    316F                       Oil                   Spain \[[@B96]\]         1994            13              2 m          38.89    E, MC, TC

  Neoparasec & NCV   Live & Killed           316F\                      Oil                   Spain \[[@B77]\]         1995            97              Adults       -10.95   F, IF, TC
                                             -                                                                                                                               

  NCV                Killed                  \-                         Oil Paraffin          Greece \[[@B97]\]        1997            226             1 m          93.27    F, MC, FC

  Neoparasec         Live                    316F                       Oil                   New Zealand \[[@B78]\]   2000            28              1-1.5 m      66.67    E, MC, TP

  Gudair             Killed                  316F                       Oil                   Australia \[[@B80]\]     2004            1200            1-4 m        90.00    F, MC, FC

  Gudair             Killed                  316F                       Oil                   Australia \[[@B98]\]     2005            \-              16 w         52.21    F, IF, FC

  Gudair             Killed                  316F                       Oil                   Australia \[[@B34]\]     2006            400             1 m          76.14    F, MC, FC

  Gudair             Killed                  316F                       Oil                   Australia \[[@B34]\]     2006            400             1 m          84.15    F, MC, FC

  Gudair             Killed                  316F                       Oil                   Australia \[[@B99]\]     2007            998             2-3 m        76.14    F, MC, FC

  Gudair             Killed                  316F                       Oil                   New Zealand \[[@B81]\]   2009            62              4 m          25.30    E, MC, FC

  NCV                Killed                  316F                       Lipid-K formulation   New Zealand \[[@B81]\]   2009            63              4 m          36.03    E, MC, FC

  NCV                Live                    316F                       Lipid-K formulation   New Zealand \[[@B81]\]   2009            63              4 m          36.03    E, MC, FC

  NCV                Live                    316F                       Lipid-K formulation   New Zealand \[[@B81]\]   2009            62              4 m          34.09    E, MC, FC

                                                                                                                                                                             

  **Average**        **76.42 ± 0.54**                                                                                                                                        

                                                                                                                                                                             

  **Goats**                                                                                                                                                                  

                                                                                                                                                                             

  Neoparasec         Live                    316F                       Oil                   France \[[@B100]\]       1988            27              1 m          73.08    E, MC, FC

  Neoparasec         Live                    316F                       Oil                   France \[[@B100]\]       1988            26              1 m          51.01    E, MC, TC

  Fromm              Killed                  \-                         Freund\'s Complete    U.S.A. \[[@B101]\]       1988            1075            1 m          80.23    F, MC, FC

  NCV                Killed                  \-                         Oil Paraffin          Greece \[[@B97]\]        1997            297             1 m          95.57    F, NVH, FC

  NCV                Killed                  Goat isolate (CWD)         QS21                  U.S.A. \[[@B102]\]       2007            20              1-4 w        61.69    E, MC, FC, TC

  NCV                Killed                  Goat isolate (CWC)         QS21                  U.S.A. \[[@B102]\]       2007            20              1-4 w        85.19    E, MC, FC, TC

  NCV                Killed                  Goat isolate (CWC)         Alum                  U.S.A. \[[@B102]\]       2007            20              1-4 w        79.31    E, MC, FC, TC

  NCV                Killed                  Goat isolate (CWD)         Alum                  U.S.A. \[[@B102]\]       2007            20              1-4 w        -57.68   E, MC, FC, TC

  NCV                Killed                  Virulent Field Strain      Alum                  India \[[@B48]\]         2007            55              4-6 m        82.14    E, MC, FC

  Gudair             Killed                  316F                       Oil                   India \[[@B48]\]         2007            55              4-6 m        52.38    E, MC, FC

  NCV                Rec                     MAP (85A, 85B, SOD, 74F)   DDA                   U.S.A. \[[@B40]\]        2009            17              5-10 d       87.50    E, MC, TC

  NCV                Rec                     MAP (85A, 85B, SOD, 74F)   none                  U.S.A. \[[@B40]\]        2009            17              5-10 d       37.50    E, MC, TC

                                                                                                                                                                             

  **Average**        **79.34 ± 0.89**                                                                                                                                        
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

NCV: non-commercial vaccine; Weybridge: Central Veterinary Laboratory, Weybridge, UK; Fromm: Fromm Laboratories, Grafton, Wisconsin USA; Lelystad: Central Veterinary Institute, Lelystad, The Netherlands; Phylaxia: Phylaxia Veterinary Biologicals Company, Budapest; Mycopar^®^: Mycopar Fort Doge/Solvay, USA; Neoparasec: Neoparasec^®^, Merial; Silirum: Silirum^®^, CZ Veterinaria/Pfizer; Lio-Johne, Ovejero, Spain; Gudair: Gudair^®^, CZ Veterinaria/Pfizer; Rec: recombinant; CWD Cell Wall Deficient MAP; CWC Cell Wall Competent MAP; P/O/P Paraffin, Olive Oil, Pumice Stone Powder; y: year(s); m: month(s); w: week(s); d: day(s); F: Field trial; E: Experimental infection; MC: Comparison to matched controls; IF: Comparison of initial versus final prevalence; NVH: Comparison to non-vaccinating herds; TC: Tissue culture; FC: Fecal culture.

###### 

Pathogenetic effects (histopathological lesions).

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Vaccine               Country and reference   Year                      Number of animals     Age at vaccination       Reduction (%)   Type of trial                       
  --------------------- ----------------------- ------------------------- --------------------- ------------------------ --------------- --------------- ---------- -------- ---------------
  **Cattle**                                                                                                                                                                 

                                                                                                                                                                             

  NCV                   Live                    6 strains                 Oil                   U.S.A. \[[@B65]\]        1935            20              calves     42.86    E, HP

  NCV                   Live                    avirulent                 P/O/P                 U.S.A. \[[@B83]\]        1974            16              16 d       17.24    E, HP

  Lelystad              Killed                  \-                        None                  Netherlands \[[@B71]\]   1992            3209            1 m        58.34    F, IF, HP

  NCV                   Killed                  \-                        Oil                   Netherlands \[[@B72]\]   1994            499             1 m        57.23    F, IF, HP

  NCV                   Killed                  \-                        Oil                   Netherlands \[[@B37]\]   1996            573             1 m        58.09    F, IF, HP

  Silirum               Killed                  316F                      Oil                   Spain \[[@B103]\]        2005            79              all ages   38.68    F, MC, HP

  Silirum               Killed                  316F                      Oil                   Spain \[[@B90]\]         2005            14              2 m        37.50    E, MC, HP

                                                                                                                                                                             

  **Average**           **57.54 ± 0.11**                                                                                                                                     

                                                                                                                                                                             

  **Sheep**                                                                                                                                                                  

                                                                                                                                                                             

  NCV                   Killed                  \-                        Oil                   Iceland \[[@B54]\]       1960            419             3 m        83.58    F, MC, PM

  NCV                   Killed                  \-                        Oil                   Iceland \[[@B54]\]       1960            24323           3 m        93.55    F, MC, PM

  NCV                   Killed                                            Oil                   U.K. \[[@B95]\]          1962            126             1 m        52.22    E, MC, HP

  Lio-Johne             Live                    316F                      Oil                   Spain \[[@B74]\]         1993            570             1 m        100.00   F, MC, HP

  Lio-Johne             Live                    316F                      Oil                   Spain \[[@B74]\]         1993            1201            Adults     53.36    F, MC, HP

  Neoparasec            Live                    316F                      Oil                   Spain \[[@B96]\]         1994            13              2 m        64.52    E, MC, HP

  Neoparasec            Live                    316F                      Oil                   Australia \[[@B104]\]    1995            475             3 m        82.27    F, MC. HP

  Neoparasec & Gudair   Live and Killed         316F                      Oil                   Spain \[[@B77]\]         1995            135             Adults     -3.03    F, IF, HP,

  Neoparasec            Live                    316F                      Oil                   New Zealand \[[@B78]\]   2000            28              1-1.5 m    77.78    E, MC, HP

  Gudair                Killed                  316F                      Oil                   Spain \[[@B105]\]        2002            12              1 m        100.00   E, MC, HP

  Mycopar               Killed                  *M.a.a*.\                 Oil                   U.S.A. \[[@B106]\]       2005            178             60-164 d   75.31    F, MC, HP
                                                Strain 18                                                                                                                    

  Neoparasec            Live                    316F                      Oil                   New Zealand \[[@B57]\]   2005            59              2-4 w      68.52    E, MC, HP

  AquaVax               Live                    316F                      saline                New Zealand \[[@B57]\]   2005            58              2-4 w      -2.48    E, MC, HP

  Gudair                Killed                  316F                      Oil                   Australia \[[@B34]\]     2006            88              1-3 m      72.70    F, MC, GL, HP

  Gudair                Killed                  316F                      Oil                   Australia \[[@B34]\]     2006            307             1-3 m      48.29    F, MC, GL, HP

  Gudair                Killed                  316F                      Oil                   New Zealand \[[@B81]\]   2009            62              4 m        75.57    E, MC, HP

  NCV                   Killed                  316F                      Lipid-K formulation   New Zealand \[[@B81]\]   2009            63              4 m        37.17    E, MC, HP

  NCV                   Live                    316F                      Lipid-K formulation   New Zealand \[[@B81]\]   2009            63              4 m        51.32    E, MC, HP

  NCV                   Live                    316F                      Lipid-K formulation   New Zealand \[[@B81]\]   2009            62              4 m        57.56    E, MC, HP

                                                                                                                                                                             

  **Average**           **89.70 ± 0.15**                                                                                                                                     

                                                                                                                                                                             

  **Goats**                                                                                                                                                                  

                                                                                                                                                                             

  NCV                   Live                    2E/316F                   P/O/P                 Norway \[[@B26]\]        1985            5535            1 m        97.18    F, IF, PM

  Gudair                Killed                  316F                      Oil                   Spain \[[@B38]\]         2000            189             Adults     65.88    F, MC, HP

  NCV                   Killed                  Goat isolate (CWD)        QS21                  U.S.A. \[[@B102]\]       2007            20              1 w        34.38    E, MC, HP

  NCV                   Killed                  Goat isolate (CWC)        QS21                  U.S.A. \[[@B102]\]       2007            20              1 w        32.03    E, MC, HP

  NCV                   Killed                  Goat isolate (CWC)        Alum                  U.S.A. \[[@B102]\]       2007            20              1 w        44.53    E, MC, HP

  NCV                   Killed                  Goat isolate (CWD)        Alum                  U.S.A. \[[@B102]\]       2007            20              1 w        -17.19   E, MC, HP

  NCV                   Killed                  Virulent Field Strain     Alum                  India \[[@B48]\]         2007            8               4-6 m      75.00    E, MC, HP

  Gudair                Killed                  316F                      Oil                   India \[[@B48]\]         2007            8               4-6 m      50.00    E, MC, HP

  NCV                   Rec                     MAP(85A, 85B, SOD, 74F)   DDA                   U.S.A. \[[@B40]\]        2009            17              5-10 d     66.67    E, MC, HP

  NCV                   Rec                     MAP(85A, 85B, SOD, 74F)   none                  U.S.A. \[[@B40]\]        2009            17              5-10 d     33.33    E, MC, HP

                                                                                                                                                                             

  **Average**           **94.79% ± 0.29**                                                                                                                                    
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

NCV: non-commercial vaccine; Lelystad: Central Veterinary Institute, Lelystad, The Netherlands; Silirum: Silirum^®^, CZ Veterinaria/Pfizer; Lio-Johne, Ovejero, Spain; Neoparasec: Neoparasec^®^, Merial; Gudair: Gudair^®^, CZ Veterinaria/Pfizer; Mycopar^®^: Mycopar Fort Doge/Solvay, USA; AquaVax; Rec: recombinant; CWD Cell Wall Deficient MAP; CWC Cell Wall Competent MAP; P/O/P Paraffin, Olive Oil, Pumice Stone Powder; y: year(s); m: month(s); w: week(s); d: day(s); F: Field trial; E: Experimental infection; MC: Comparison to matched controls; IF: Comparison of initial versus final prevalence; GL: Gross lesions; HL: Histological lesions.

The vast majority of studies on all species showed positive reductions in all examined variables (Figure [2](#F2){ref-type="fig"}), that in cattle resulted in average reductions of 96.0%, 72.6% and 57.5% for production, epidemiological or pathogenetic effects, respectively. In sheep these reductions were of 67.5%, 76.4% and 89.7% and in goats of 45.1%, 79.3% and 94.8%, clearly demonstrating that MAP vaccination works well in all three species. The widest spread in reduction percentages, including several negative reduction rates, was observed with the epidemiological effects variable, which represents culture data. These differences are probably due to inherent aspects of each variable, since frequently the same study that gave negative reduction rates with the epidemiological variable, showed much better reduction results with the other variables, specially for the production effects variable. Most studies reported culture data as positive or negative result and did not include data on quantification of bacterial load in the sample. Thus, vaccinated animals with clinical signs reduction were still infected and excreted bacteria. This would imply that even though the amount of bacterial shedding might have been reduced, the proportion of shedding animals might have not. As a consequence, this would be in agreement with the widely accepted concept that, in general, current MAP vaccines can contain the infection and dramatically decrease clinical signs in a herd, but do not completely clear the infection.

![**Types of MAP vaccination experiments used in the meta-analysis**. Graphic representation of MAP vaccination experiments grouped by outcome according to animal species and category (production, epidemiological or pathogenetic effects). Experiments with a negative outcome: bars on the left part of the chart; experiments with a positive outcome: bars on the right hand of the chart. Numbers adjacent to the bars correspond to the number of experiments. \*One experiment has a 0% reduction.](1476-8518-9-8-2){#F2}

Except for a few cases, vaccination in cattle was applied at early ages, in the first weeks of life, while in sheep more studies included adult sheep. The largest sample size studies, up to 150,000 animals, were done in cattle and preferentially recorded production effects in terms of paratuberculosis culling rates, since measurement of the other variables is much more time-consuming and costly. This is also reflected in the median sample size for the studies that looked at the production variable, 876, 700, and 4975 animals for cattle, sheep and goat studies, respectively, while studies analyzing the epidemiological or pathogenetic variables had median sizes around 100 or less.

The range of study length was between a few months and 16 years covering a period of 74 years. A large increase in sheep studies in the last decade coincided with the availability of the successful small ruminant commercial vaccine Gudair™ and its extended application in Australia and New Zealand. In the majority of the studies (68 experiments) killed vaccines were used. Most experiments used MAP strain 316F from Weybridge, nine used Strain 18 (now known to be *M. avium*subsp. *avium*rather than MAP \[[@B56]\]), and the rest used local isolates or subunit vaccines consisting of recombinant proteins. Not surprisingly, 316F is the most frequently used strain in sheep studies, since the above mentioned commercial vaccine for sheep and goats is based on this strain. Bacterial content varied widely, from 1000 CFU to 3 × 10^9^CFU, and from 2.5 mg to 100 mg. The large majority of studies used some type of oily adjuvant (mineral oil, olive oil, liquid paraffin etc.) and in very few cases alum. In one study \[[@B57]\], AquaVax experimental vaccine was used, which contains no adjuvant but saline instead. More recent studies have started using other newer adjuvants such as MPLA, RIBI, cytokines, DDA, QS21, and lipid formulations, some of them with good results.

Discussion
==========

A wide variation in the efficacy of vaccines was observed, especially in cattle and sheep, where negative reductions are described in some studies. However, the overall results are pretty homogeneous, with very small error ranges due to the large numbers of observations included. In general, vaccine strain or administration route differences do not seem to substantially alter the outcome of vaccination, however, type of antigen formulation or adjuvant appears to have been important in a few experimental studies where different formulations were compared side by side \[[@B58]\].

The goal of this review was to evaluate vaccination as a whole, summarizing the results into a single table for each type of measure used to determine vaccine success. This analysis has revealed that, in average, vaccination has a positive effect. However, since the efficacy figures are rather poor in comparison to vaccines for other microorganisms, it is relevant to at least try to discuss possible reasons for some of the low success rates. In order to simplify, one possible approach is to find an explanation for studies where vaccination performed below the average. Production effect studies where the measurement was total mortality may be considered flawed because in most cases mortality did not differentiate between paratuberculosis and other pathologies, possibly diluting the \"vaccine effect\". This is evident in the case of sheep and goat trials were adults were considered. Since the more sensitive part of the population might have already died of paratuberculosis before vaccination the remaining animals could be considered more resistant to paratuberculosis, and therefore, less likely to show any effect of vaccine protection. Because young animal studies showed larger effects, this becomes a very likely explanation for low reduction rates. An additional explanation for the poor results could be the fact that, frequently, vaccination programs coincide with the initiation of other control measures making it difficult to assess the real effect of the vaccine on paratuberculosis control.

Under the epidemiological effects analyzed, reduction in the proportion of fecal shedders appears to be one of the measurements showing the widest variability. This happens mostly in small studies or in studies carried out in the Netherlands. Besides the qualitative effects in terms of protection conferred, vaccination should be assessed from another, perhaps even more important standpoint, such as is the reduction of amounts of bacteria shed by vaccinated and non-vaccinated animals.

When considering reduction in pathogenetic effects, it should be pointed out that some of the studies had a very short follow up and that the presence of focal lesions of paratuberculosis are weighted the same as the presence of large areas of affected intestine.

Since the vast majority of the studies show a positive effect, the question as to why vaccination has not been given more opportunities comes out with force. Especially, because for years MAP eradication efforts have only shown very moderate success or straight failure due to their enormous costs and frequent relapses of infected animals. Already in the eighties \[[@B59]\] and nineties \[[@B37],[@B60]\] several studies showed the profitability of vaccination. Over a period of a few years, the economic advantages of vaccination may be up 20 times higher than any testing and culling strategy which, in addition to yielding uncertain results, it results in a much higher economic cost. Other strategies based on certification are compatible with vaccination, and moreover, vaccination might allow a spectrum of other approaches to paratuberculosis control dependant on the financial resources of the farm, region or farmers association, and the actual economic losses sustained by the enterprise. It has been estimated that only a 5% annual clinical incidence of paratuberculosis will justify entering a mixed vaccination and testing and culling strategy \[[@B61]\].

In our opinion, there is a mixture of vested interests on control programs based in testing and culling, simplistic thinking comparing tuberculosis and paratuberculosis, fear of cross-reactions, academic detachment and confusion between ideal objectives and practical needs for the livestock industry. It is clear that the main reason for the opposition to MAP vaccination in cattle has been the problem of expected interference with the diagnosis of tuberculosis and its consequences in trade and national TB programs, however, the availability of an OIE official test -the comparative intradermal tuberculin test- that can very easily solve this problem in the majority of cases, should eliminate this concern on MAP vaccination in cattle. Recent field vaccination trials in cattle with an experimental MAP vaccine (Silirum™, CZV), have shown that less than 0.5% of vaccinated animals will give interference problems when the comparative intradermal tuberculin test is used even if the most restrictive interpretation of results proposed by the OIE is applied (Joseba Garrido, personal communications). The benefits obtained from production increases and reduction in clinical cases of MAP, will largely outweigh the small loss due to culling of these tuberculosis cross-reactive animals. In addition, new plans for the introduction of improved tuberculosis vaccines for cattle \[[@B62]\], will also affect the prospects of MAP vaccination in cattle, since the accompanying DIVA diagnostic test will probably allow for the identification of MAP infected or vaccinated animals.

MAP vaccination concerns in cattle have been further aggravated by the fear of the dairy industry to a crisis of confidence in their products, particularly, if a potential zoonotic link between paratuberculosis and a human disease (IBD/Crohn\'s disease) is confirmed \[[@B63]\] or if too much discussion and research efforts are focused on this subject. At this moment in which the paratuberculosis scientific community has finally accepted that the key to the paratuberculosis problem might not be eradication, but just control, vaccination offers the solution to this problem, since it not only allows to confine the paratuberculosis problem within the limits of a livestock production issue, while downright calming the worries of farmers, but also provides the perfect cover for doing something against paratuberculosis from a Public Health point of view, without incurring in massive costs. Vaccination might be the beginning of the end of the huge worldwide paratuberculosis problem and might mark the difference between doing nothing and advancing towards global control \[[@B64]\].

Conclusions
===========

Paratuberculosis control poses a though challenge for farmers and veterinarians. Test and cull strategies can be useful in some settings but do not seem to have reached extensive success. Control by vaccination is an alternative that has been longtime in use in some regions and species. A substantial number of vaccination studies where objective information is amenable to meta-analysis treatment have been published in peer reviewed journals or in conference proceedings or other media. The high heterogeneity among reports makes it difficult to accept that the narrow statistical confidence interval obtained in these meta-analyses actually represents the true range of reduction in the whole set of trials. However, the results analyzed here clearly show a general positive effect from vaccination, negative effects only in a few trials, and a positive average balance according to all three variables considered (production, epidemiological or pathogenetic effects). In terms of quantitative reduction, the minimum is an 11% reduction in MAP isolation, which could be considered the worst case average, but with a common outcome at over 50% which is highly profitable from a production point of view. This strategy thus has high chances of have a effect on the overall environmental contamination with MAP, which would mean a significant advance in the fight against paratuberculosis, both in the animal and in the (potential) human public health fields.
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